PATENT CLAIM ANALYSIS

Application Number: 16218383
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "108000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions.

Claim (Index 1):
A method of treating pain not related to cancer, comprising: orally administering a dosage form comprising zoledronic acid, in an acid form or a salt form, to a human being in need of treatment with zoledronic acid, wherein the human being has fasted for at least one hour before the dosage form is orally administered and the human being fasts for at least one hour after the dosage form is orally administered; with the proviso that the bioavailability of zoledronic acid resulting from orally administering the dosage form is no more than 4%; wherein the dosage form contains no less than 40 mg of the zoledronic acid; and with the proviso that the bioavailability of zoledronic acid resulting from orally administering the dosage form is at least 1.1%.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 98.0
- Lexical Diversity: 1.14815
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15587108', '15378939', '15439774', '15801049', '15697267']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8239654807637508
- 35 USC 102 Novelty (BERT): 0.5948779343132263
- Combined Prediction Score: 0.8010567261186983
- Mean Citation Score: 577.502648
- Max Citation Score: 579.5003
- Similarity Product: 438.3481478517354

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test